Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. Read more about Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women.
Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. Read more about Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. Read more about Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.
Active smoking, household passive smoking, and breast cancer: evidence from the California Teachers Study. Read more about Active smoking, household passive smoking, and breast cancer: evidence from the California Teachers Study.
Determinants of BRAF mutations in primary melanomas. Read more about Determinants of BRAF mutations in primary melanomas.
Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. Read more about Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy.
RESPONSE: Re: Mammographic Breast Density and Family History of Breast Cancer. Read more about RESPONSE: Re: Mammographic Breast Density and Family History of Breast Cancer.
Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. Read more about Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. Read more about Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. Read more about Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma.
